THERAPY DOSSIER · th-7b9846f60cfc

miR-381-3p overexpression (miR-381-3p mimic in vitro; miR-381-3p overexpression in vivo)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30229813 ↗2018Reported benefit

Overexpression of miR-381-3p promotes the recovery of spinal cord injury.

RatSpinal cord injuryUnspecifiedSprague-DawleyFemale per MeSH indexing

Model: Acute spinal cord injury rat model; parallel in vitro model of lipopolysaccharide-stimulated BV2 microglial cells

miR-381-3p was downregulated after acute spinal cord injury while IKKbeta and phospho-p65 were upregulated; miR-381-3p overexpression reduced IKKbeta, phospho-p65, TNF-alpha and IL-1beta and produced earlier recovery of grip ability, coordination and anti-fatigue performance, consistent with inhibi…

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…